Method and System for Reducing the Likelihood of Colorectal Cancer in a Human Being

• US 20190029871A1
• Filed: 09/26/2018
• Published: 01/31/2019
• Est. Priority Date: 02/04/2011
• Status: Active Grant

• Current Assignee: Seed Health, Inc.
• Original Assignee: Joseph E. Kovarik
• Inventors: Kovarik, Joseph E.
• Granted Patent: US 10,548,761 B2
• Time in Patent Office: Days
• CPC Class Codes: A61F 5/566 Intra-oral devices
• CPC Class Codes: A61K 31/733 Fructosans, e.g. inulin
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual'"'"'s gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

Claims

1. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising:

administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii;

providing fructan fiber inulin in an amount sufficient to reduce the pH in the colon of the human being; and

acidifying of the colon to enhance intestinal Ma.sup.2+ absorption by the human being.

2. The method of claim 1, wherein the Faecalibacterium prausnitzii bacteria employed are from the human being treated and are first isolated from the person'"'"'s stool.

3. The method of claim 1, further comprising enhancing the integrity of the intestinal barrier in the individual human being by increasing the amount of mucin produced by Prevotella species in the individual human being.

4. The method of claim 1, wherein the F. prausnitzii is modified to produce enhanced levels of butyrate to inhibit biofilm formation and activity of pathogens.

5. The method of claim 1, wherein a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system is employed to increase butyrate production of by the F. prausnitzii.

6. The method of claim 1, further comprising the parallel administration of a prebiotic.

7. The method of claim 1, wherein the increased butyrate production results in a beneficial effect to the human being comprising improving the individual human being'"'"'s gut barrier integrity.

8. The method of claim 1, wherein the F. prausnitzii bacterial population is administered to an individual in preferred ratios that reflect those of healthy individuals so as to attain the general balance of said bacterial population in the individual human being'"'"'s gut.

9. The method of claim 1, wherein the F. prausnitzii bacterial population is selected that is effective in inhibiting biofilm formation.

10. The method of claim 1, wherein said step of administering a therapeutically effective amount of a bacterial formulation achieves elevated relative concentration of butyrate in the gut of the individual human being.

11. The method of claim 1, wherein the step of administering a therapeutically effective amount of a bacterial formulation is by oral administration.

12. The method of claim 1, wherein the step of administering a therapeutically effective amount of a bacterial formulation reduces inflammation in the gut of the individual human being.

13. The method of claim 1, further comprising the reduction of pathogenic resident microbes in the gut of the individual human being.

14. The method of claim 1, further comprising the reduction of H. pylori populations in the individual human being.

15. The method of claim 1, further comprising the modification of H. pylori resistance to antibiotics, including the retention and maintenance of lipid A production.

16. The method of claim 1, further comprising, employing a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system CRISPR/Cas to rid Prevotella bacteria of virulence factors selected form the group of fimbria, hemolysins, adhesions and hemagglutinins and administration of said Prevotella bacteria to the individual human being.

18. The method of claim 1, wherein the Faecalibacterium prausnitzii bacteria employed are from the human being treated and are first isolated from the person'"'"'s stool.

19. The method of claim 1, further comprising enhancing the integrity of the intestinal barrier in the individual human being by increasing the amount of mucin produced by Prevotella species in the individual human being.

17. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising:

substantially reducing the human being'"'"'s resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii;

providing fructan fiber inulin in an amount sufficient to reduce the pH in the colon of the human being; and

acidifying of the colon to enhance intestinal Ma.sup.2+ absorption by the human being.

20. A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising:

substantially reducing the human being'"'"'s resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii;

providing fructan fiber inulin in an amount sufficient to reduce the pH in the colon of the human being; and

acidifying of the colon to enhance intestinal Ma.sup.2+ absorption by the human being, wherein said method comprises a step of administering a therapeutically effective amount of a bacterial composition comprising F. prausnitzii adapted to produce butyrate, wherein the F. prausnitzii has been modified via a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system to produce butyrate.